FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023513295> ?p ?o ?g. }

• W3023513295 abstract "Abstract We report the outcome of children with Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) treated on the national trial for childhood ALL, MRC ALL 97/99, between Jan 1997 and Jun 2002. A diagnosis of Ph+ ALL was made by karyotyping and/or fluorescent in situ hybridisation. Outcome was evaluated according to NCI risk criteria and treatment response. Statistical methods included Kaplan Meier analysis, logrank and stratified logrank tests. Of the 1937 patients treated on the MRC ALL 97/99 protocol, 1836 were successfully screened for Ph chromosome and 42 (2.3%) were positive. This subgroup of patients was heterogeneous at the cytogenetic level with 27 (77%) out of 35 assessable cases having one or more abnormality in addition to the Ph translocation. Four recurrent secondary abnormalities were observed: an extra Ph chromosome, loss of 9p (del 9p), high hyperdiploidy and monosomy 7. The median age at diagnosis and presenting white cell count were 6.8 years and 32.5 × 109/L respectively. 19 (45%) had <25% bone marrow blasts within the first two weeks of treatment and were defined as a Good-response group (GRG), the others were classified as a Poor-response group (PRG). 6/10 (60%) of the patients with an extra Ph chromosome were in the GRG, whereas 8/10 (80%) of those with del 9p belonged to the PRG. 36/42 (86%) achieved complete remission (CR1) at the end of induction of whom 28 underwent bone marrow transplantation (BMT). The median follow up was 41 months (range 21–84 months). The 3-year estimate for event free survival (EFS) (with 95% confidence intervals) was 57% (41–70%). The EFS for the GRG and PRG were 74% (48–88%) and 44% (22–64%) respectively. Significant predictors for survival were presenting white cell count (p=0.02) and early response to treatment (p=0.03), but not age at diagnosis or gender. BMT in CR1 appeared to reduce the risk of a subsequent bone marrow relapse. These results are a significant improvement on previous results, particularly for the PRG. The EFS for the PRG in this report is 44% compared to a 4 yr. EFS of 10% in previously published data from the BFM/AIEOP group. We believe that the early introduction of intensive chemotherapy as in the MRC trial improves early response rates and overall outcome in Ph+ ALL, especially for the PRG. BMT in CR1 is recommended in children with Ph+ ALL, nonetheless newer alternative treatment strategies, such as the use of imatinib mesylate need to be evaluated for children with Ph+ ALL." @default.
• W3023513295 created "2020-05-13" @default.
• W3023513295 creator A5004954447 @default.
• W3023513295 creator A5020331524 @default.
• W3023513295 creator A5032713965 @default.
• W3023513295 creator A5036248506 @default.
• W3023513295 creator A5039126778 @default.
• W3023513295 creator A5053476959 @default.
• W3023513295 creator A5066319509 @default.
• W3023513295 creator A5069665879 @default.
• W3023513295 creator A5071432225 @default.
• W3023513295 creator A5083456305 @default.
• W3023513295 creator A5087351248 @default.
• W3023513295 date "2004-11-16" @default.
• W3023513295 modified "2023-09-30" @default.
• W3023513295 title "Early Response to Induction Is Predictive of Survival in Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia: Results of the Medical Research Council ALL 97 Trial." @default.
• W3023513295 doi "https://doi.org/10.1182/blood.v104.11.165.165" @default.
• W3023513295 hasPublicationYear "2004" @default.
• W3023513295 type Work @default.
• W3023513295 sameAs 3023513295 @default.
• W3023513295 citedByCount "0" @default.
• W3023513295 crossrefType "journal-article" @default.
• W3023513295 hasAuthorship W3023513295A5004954447 @default.
• W3023513295 hasAuthorship W3023513295A5020331524 @default.
• W3023513295 hasAuthorship W3023513295A5032713965 @default.
• W3023513295 hasAuthorship W3023513295A5036248506 @default.
• W3023513295 hasAuthorship W3023513295A5039126778 @default.
• W3023513295 hasAuthorship W3023513295A5053476959 @default.
• W3023513295 hasAuthorship W3023513295A5066319509 @default.
• W3023513295 hasAuthorship W3023513295A5069665879 @default.
• W3023513295 hasAuthorship W3023513295A5071432225 @default.
• W3023513295 hasAuthorship W3023513295A5083456305 @default.
• W3023513295 hasAuthorship W3023513295A5087351248 @default.
• W3023513295 hasConcept C104317684 @default.
• W3023513295 hasConcept C10515644 @default.
• W3023513295 hasConcept C109748351 @default.
• W3023513295 hasConcept C126322002 @default.
• W3023513295 hasConcept C138626823 @default.
• W3023513295 hasConcept C143998085 @default.
• W3023513295 hasConcept C174475383 @default.
• W3023513295 hasConcept C187212893 @default.
• W3023513295 hasConcept C2778461978 @default.
• W3023513295 hasConcept C2778904597 @default.
• W3023513295 hasConcept C2779142324 @default.
• W3023513295 hasConcept C2780189214 @default.
• W3023513295 hasConcept C2781107101 @default.
• W3023513295 hasConcept C2909962599 @default.
• W3023513295 hasConcept C30481170 @default.
• W3023513295 hasConcept C53226629 @default.
• W3023513295 hasConcept C54355233 @default.
• W3023513295 hasConcept C66339696 @default.
• W3023513295 hasConcept C71924100 @default.
• W3023513295 hasConcept C86803240 @default.
• W3023513295 hasConcept C90924648 @default.
• W3023513295 hasConceptScore W3023513295C104317684 @default.
• W3023513295 hasConceptScore W3023513295C10515644 @default.
• W3023513295 hasConceptScore W3023513295C109748351 @default.
• W3023513295 hasConceptScore W3023513295C126322002 @default.
• W3023513295 hasConceptScore W3023513295C138626823 @default.
• W3023513295 hasConceptScore W3023513295C143998085 @default.
• W3023513295 hasConceptScore W3023513295C174475383 @default.
• W3023513295 hasConceptScore W3023513295C187212893 @default.
• W3023513295 hasConceptScore W3023513295C2778461978 @default.
• W3023513295 hasConceptScore W3023513295C2778904597 @default.
• W3023513295 hasConceptScore W3023513295C2779142324 @default.
• W3023513295 hasConceptScore W3023513295C2780189214 @default.
• W3023513295 hasConceptScore W3023513295C2781107101 @default.
• W3023513295 hasConceptScore W3023513295C2909962599 @default.
• W3023513295 hasConceptScore W3023513295C30481170 @default.
• W3023513295 hasConceptScore W3023513295C53226629 @default.
• W3023513295 hasConceptScore W3023513295C54355233 @default.
• W3023513295 hasConceptScore W3023513295C66339696 @default.
• W3023513295 hasConceptScore W3023513295C71924100 @default.
• W3023513295 hasConceptScore W3023513295C86803240 @default.
• W3023513295 hasConceptScore W3023513295C90924648 @default.
• W3023513295 hasLocation W30235132951 @default.
• W3023513295 hasOpenAccess W3023513295 @default.
• W3023513295 hasPrimaryLocation W30235132951 @default.
• W3023513295 hasRelatedWork W177082538 @default.
• W3023513295 hasRelatedWork W1999463022 @default.
• W3023513295 hasRelatedWork W2005775902 @default.
• W3023513295 hasRelatedWork W2013900672 @default.
• W3023513295 hasRelatedWork W2038099628 @default.
• W3023513295 hasRelatedWork W2325088380 @default.
• W3023513295 hasRelatedWork W3023513295 @default.
• W3023513295 hasRelatedWork W4248139982 @default.
• W3023513295 hasRelatedWork W4248988585 @default.
• W3023513295 hasRelatedWork W90210489 @default.
• W3023513295 isParatext "false" @default.
• W3023513295 isRetracted "false" @default.
• W3023513295 magId "3023513295" @default.
• W3023513295 workType "article" @default.